Compare Taskus Inc (TASK) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs Zimmer Biomet Holdings Inc — how do they compare? Taskus Inc trades at $7.59 (market cap $700.49M), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 25.7× Taskus Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| TASK | ZBH | |
|---|---|---|
Market Cap | $700.49M | $17.97B |
Sector | Technology | Health |
52-Week High | $18.03 | $104.26 |
52-Week Low | $4.57 | $79.58 |
Enterprise Value | $1.07B | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $7.65, down 3.29% today, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income of $102.28M, yielding attractive valuation ratios including a P/E of 6.59 and P/S of 0.58. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI Services growth.
The stock presents value opportunity with discounted multiples and analyst consensus target of $8.00 (4.6% upside). Risks include client concentration and competitive pressures in digital services. Institutional interest remains positive with Dimensional Fund increasing holdings by 12.8% in Q1 2026.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
